Business Parks & Science Centres

 
 
 

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Medicines Discovery Catapult, The. (10/22/18). "Press Release: Overcoming Bottlenecks in Early Drug Discovery with the Power of Sound. Medicines Discovery Catapult and AstraZeneca Collaborate to Unlock the Potential of Acoustic Mist Ionisation Mass Spect

Region Region United Kingdom (GB)
Organisations Organisation Medicines Discovery Catapult Ltd. (MD Catapult) (GB)
  Group United Kingdom (GB) (govt)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product acoustic mist ionisation mass spectrometry (AMI-MS)
  Product 2 drug discovery
Index term Index term AstraZeneca–United Kingdom (govt): mass spectrometry, 201810– collab with Medicinces Discovery Catapult on acoustic mist ionisation mass spectrometry
     


Medicines Discovery Catapult have today [22nd October] announced a collaboration with AstraZeneca to advance the adoption of Acoustic Mist Ionisation Mass Spectrometry (AMI-MS) within drug discovery.

For the first time UK small and medium-sized enterprises (SMEs) will have access to this state-of-the-art bioanalytical technology through research partnerships with the Catapult. The collaboration will also enable AstraZeneca to further unlock the potential of AMI-MS by accessing Medicines Discovery Catapult’s technical expertise.

Although a powerful technique used to determine the mass, structure and abundance of molecules, traditional mass spectrometry has limitations in the rate at which samples can be introduced into the mass detector. The industry has therefore relied on other expensive labelled technologies that increase the duration and cost of early stage drug discovery.

AMI-MS delivers a twenty-fold improvement in throughput compared to traditional mass spectrometry. Instead of using a needle to inject a liquid sample into the mass detector, AMI technology uses sound energy. A fine mist of charged droplets is ‘lifted’ from the surface of a sample into the mass spectrometer. Contactless and contamination-free, AMI-MS can analyse up to three samples per second, or more than 100,000 samples per day.

Dr Peter Simpson, Chief Scientific Officer of the Medicines Discovery Catapult, says:
“It is important for us to enable UK SMEs to use hard-to-access sophisticated bioanalytical technologies. For the first time, using the power of sound energy, this state-of-the-art technology gives our partner SMEs the potential to better understand and more rapidly advance their promising drug candidates.”


Dr Jon Wingfield, Principal Scientist, Innovative Medicines and Early Development (IMED) Biotech Unit at AstraZeneca says:
“We are investing in ground-breaking science to help lead the way in mass spectrometry screening. Our collaboration with Medicines Discovery Catapult will not only enable us to engage with the wider scientific community but will also allow us to unlock the potential of Acoustic Mass Spectrometry within drug discovery.”

- End –


For further information or to arrange interviews contact Lisa Bedwell on 01625 708395 or
07741 857132 or email media@md.catapult.org.uk


Notes to Editors:


About the Medicines Discovery Catapult

The Medicines Discovery Catapult is a national centre of applied Research and Development expertise, uniquely designed to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects.

It is one of a network of elite, not-for-profit technology and innovation centres established by Innovate UK as a long-term investment in the UK’s economy. The Medicines Discovery Catapult will work with industry, academic teams, technology experts, charities, regulators and others.

We provide unique scientific capabilities and act as a gateway to specialist facilities, technology and expertise within the UK, supporting SMEs to drive the development of new approaches for the discovery and early development of new medicines. Helping to transform ideas into commercial products and services for the wider health and wealth of the country.

By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, it can help the UK maintain its heritage position as a global leader in this key industry.

https://md.catapult.org.uk/ @MedDiscCat

   
Record changed: 2018-11-03

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for United Kingdom (GB) (govt)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top